Clinical Trial Update: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Brentuximab Vedotin with R-CHP in newly diagnosed EBV-positive diffuse large B-cell lymphoma, NOS; the study is not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Ebv-positive Diffuse Large B-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin | Phase 2 | Status: NOT_YET_RECRUITING